Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma

Sep 17, 2012 No Comments by Casey

This study looks at what effects (good and bad) a drug called PXD-101 (belinostat) in
combination with the radioactive drug Zevalin (yttrium Y 90 ibritumomab tiuxetan) has on
patients with relapsed aggressive (high-risk) non-Hodgkin lymphoma. Studies in the
laboratory suggest that drugs such as PXD101 can act upon specific cancer cell processes to
cause either death of the cancer cells or prevention of their growth. In human studies with
a small number of patients with this lymphoma, PXD-101 has shown the ability to shrink and
slow tumor growth. When Zevalin is delivered directly to the tumor, the lymphoma cells are
destroyed and this may result in the disappearance of the tumor (remission)

Clinical Trial Conditions: Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma

Treatments in this Clinical Trial : belinostat, rituximab, yttrium Y 90 ibritumomab tiuxetan

Clinical Trial Phase: Phase 2

Eligible Clinical Trial Participant Age : Between 18 years to 100 years

Can Healthy Volunteers Participate: No

Clinical Trial Lead Sponsor: Thomas P. Miller

Detailed Clinical Trial Description: This study looks at what effects (good and bad) a drug called PXD-101 (belinostat) in
combination with the radioactive drug Zevalin (yttrium Y 90 ibritumomab tiuxetan) has on
patients with relapsed aggressive (high-risk) non-Hodgkin lymphoma. Studies in the
laboratory suggest that drugs such as PXD101 can act upon specific cancer cell processes to
cause either death of the cancer cells or prevention of their growth. In human studies with
a small number of patients with this lymphoma, PXD-101 has shown the ability to shrink and
slow tumor growth. When Zevalin is delivered directly to the tumor, the lymphoma cells are
destroyed and this may result in the disappearance of the tumor (remission)

The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01686165

New Clinical Trial